-
Mashup Score: 4High Levels of CD163+ Tumor-Associated Macrophages Could Improve Outcomes With Nivolumab in Metastatic RCC - 12 hour(s) ago
High levels of CD163-positive TAMs and exhausted CD8-positive TILs could potentially affect efficacy results in metastatic RCC by reprogramming TAMs.
Source: www.onclive.comCategories: General Medicine NewsTweet
-
Mashup Score: 5Metastasis-Directed Radiotherapy Yields Durable Disease Control Without Systemic Therapy in Oligometastatic RCC - 19 hour(s) ago
Metastasis-directed radiotherapy without systemic therapy demonstrated an improved safety profile vs immunotherapy and tyrosine kinase inhibitors.
Source: www.onclive.comCategories: General Medicine NewsTweet-
In patients with oligometastatic clear cell #RCC, treatment with radiotherapy without concurrent systemic therapy resulted in a median PFS of 34.0 months, a median systemic therapy-free survival of 17.7 months, and a 3-year OS rate of 86.5%. Read here: https://t.co/Pln7YN2QdN
-
-
Mashup Score: 10
KIM-1 levels have shown the ability to predict therapeutic benefit in patients with renal cell carcinoma.
Source: www.onclive.comCategories: General Medicine NewsTweet-
The biomarker KIM-1 has emerged as a potential prognostic indicator for response to therapy and could be used to inform clinical decision making for patients with #RCC. @VincentWenxinXu @DanaFarberNews Read here: https://t.co/61e6lg1qiY https://t.co/gJCjVajal0
-
-
Mashup Score: 7Novel CAR T-Cell Therapy Could Pave the Way for Improvements in Advanced ccRCC Management - 2 day(s) ago
Research supports the use of novel CAR T-cell therapy targeting CAIX and CD70 for the treatment of patients with advanced ccRCC.
Source: www.onclive.comCategories: General Medicine NewsTweet-
The novel CAR T-cell therapy strategy is being developed to be dual-targeted and immune-restoring, and pending clinical investigation, it may be a path toward curing a certain subtype of clear cell #RCC. @marasco_wayne @danafarbernews Read here: https://t.co/FhdPMlTWb9 https://t.co/BMud32p8ts
-
-
Mashup Score: 5Belzutifan Prolongs Quality-Adjusted Time Without Symptoms or Toxicity in Advanced RCC - 2 day(s) ago
Treatment with belzutifan increased the time without progression or toxicity vs everolimus in patients with advanced RCC.
Source: www.onclive.comCategories: General Medicine NewsTweet-
A Q-TWiST analysis of the phase 3 LITESPARK-005 trial showed that belzutifan yielded a clinically meaningful improvement in quality-adjusted survival time vs everolimus for patients with advanced #RCC. Read here: https://t.co/INPKHDgi9K https://t.co/8ha5PbQGJa
-
-
Mashup Score: 1Chromophobe RCC Microenvironment Study Shows Determinants of Impaired Antitumor Immunity - 3 day(s) ago
Although chromophobe RCC has an immune-cold environment, ferroptosis induction may be a promising target for managing tumor resistance in this subtype.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Chromophobe RCC Microenvironment Study Shows Determinants of Impaired Antitumor Immunity #RCC https://t.co/eNYiIesWls
-
-
Mashup Score: 6Machine Learning–Based Approach Improves Outcome Prediction vs Individual Biomarkers in RCC - 2 month(s) ago
The evaluation of diverse biomarkers via a machine learning approach demonstrated improved prediction of clinical outcomes vs individual biomarkers in RCC.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Machine Learning–Based Approach Improves Outcome Prediction vs Individual Biomarkers in RCC @BraunMDPhD @YaleCancer #RCC https://t.co/syyhJdtECT
-
-
Mashup Score: 3Combination Regimens Offer Options in Frontline RCC as Novel Agents Advance Through Pipeline - 3 month(s) ago
During an OncLive Peer Exchange filmed during ASCO GU, expert investigators discussed significant updates in the RCC space.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Combination Regimens Offer Options in Frontline RCC as Novel Agents Advance Through Pipeline @katy_beckermann @PBarataMD @MosheOrnsteinMD #RCC https://t.co/duG98eS5wg
-
-
Mashup Score: 7ASCO GU 2025: Optimizing Treatment Selection and Clinical Decision-Making in Advanced RCC - 3 month(s) ago
Experts discuss the evolving treatment landscape in advanced renal cell carcinoma (RCC), focusing on optimal treatment selection and sequencing strategies, with insights from recent clinical trial updates presented at ASCO GU 2025 and their potential impact on clinical practice.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Watch as @PBarataMD, @MosheOrnsteinMD, Elizabeth Wulff-Burchfield, MD, and @katy_beckermann discuss the 8-year follow-up from CheckMate 214, evaluating nivolumab plus ipilimumab for first-line treatment of advanced #RCC Watch more here: https://t.co/8pr5hE2hvy
-
-
Mashup Score: 8
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine NewsTweet-
In a small, Phase I clinical trial led by Dana Farber researchers, all patients had durable immune responses to a personalized cancer vaccine for advanced renal cell carcinoma. https://t.co/7Wu1mneGAd #RCC https://t.co/UHANm0m5nJ
-
The efficacy of PD-1 blockade may be mediated by reprogramming tumor-associated macrophages, as high levels of CD163+ TAMs are associated with improved outcomes to anti–PD-1 therapy in metastatic clear cell #RCC. @simsek_berkay_ @BrighamWomens Read here: https://t.co/LCGr34jKmy https://t.co/ddNYzbcg0j